Securities code: Hybio Pharmaceutical Co.Ltd(300199) securities abbreviation: Hybio Pharmaceutical Co.Ltd(300199) Announcement No.: 2022033 Hybio Pharmaceutical Co.Ltd(300199)
Announcement on the resolution of the fourth meeting of the Fifth Board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
Hybio Pharmaceutical Co.Ltd(300199) (hereinafter referred to as "the company" or " Hybio Pharmaceutical Co.Ltd(300199) ") sent the notice of convening the fourth meeting of the Fifth Board of supervisors to all supervisors of the company by e-mail and telephone notice on March 22, 2022.
The meeting was held at 11:00 a.m. on March 24, 2022 in the conference room on the first floor of the company in the form of on-site combined communication. Three supervisors should be present at the meeting, three actually present, and some senior managers attended the meeting as nonvoting delegates.
The convening and convening of this meeting comply with the relevant provisions of the company law of the people's Republic of China and the articles of association, and the resolutions of the meeting are legal and effective.
2、 Deliberation at the meeting of the board of supervisors
(I) deliberated and passed the proposal on the company's 2022 restricted stock incentive plan (Draft) and its summary;
After review, The board of supervisors believes that the contents of the Hybio Pharmaceutical Co.Ltd(300199) 2022 restricted stock incentive plan (Draft) (hereinafter referred to as the "incentive plan") and its abstract comply with the company law of the people's Republic of China (hereinafter referred to as the "company law"), the securities law of the people's Republic of China (hereinafter referred to as the "Securities Law"), the measures for the administration of equity incentive of listed companies, and the Listing Rules of GEM stocks of Shenzhen Stock Exchange And other relevant laws, regulations and normative documents. The implementation of this incentive plan will improve the medium and long-term incentive and restraint mechanism of the company, make the interests of core employees more closely combined with the long-term development of the company and shareholders, fully mobilize the enthusiasm and creativity of key employees, which is conducive to the sustainable development of the company and does not damage the interests of the company and all shareholders.
For details, see the relevant announcement of the company published on cninfo.com, the gem information disclosure website designated by the CSRC on March 25, 2022.
Voting result: Yes: 3 votes; Against: 0 votes; Abstention: 0 votes.
This proposal still needs to be submitted to the general meeting of shareholders for deliberation.
(II) deliberated and passed the proposal on the management measures for the implementation and assessment of the company's restricted stock incentive plan in 2022;
After review, the board of supervisors believes that the measures for the administration of the implementation and assessment of the restricted stock incentive plan of Shenzhen Hanyu Pharmaceutical Co., Ltd. in 2022 aims to ensure the smooth implementation of the company's incentive plan, ensure the standardized operation of the incentive plan, comply with the provisions of relevant laws and regulations and the actual situation of the company, further improve the corporate governance structure and form a good and balanced value distribution system, It is conducive to the sustainable development of the company and does not damage the interests of the company and all shareholders.
For details, see the relevant announcement of the company published on cninfo.com, the gem information disclosure website designated by the CSRC on March 25, 2022.
Voting result: Yes: 3 votes; Against: 0 votes; Abstention: 0 votes.
This proposal still needs to be submitted to the general meeting of shareholders for deliberation.
(III) deliberated and passed the proposal on verifying the list of incentive objects first granted by the company's restricted stock incentive plan in 2022;
After examination, the board of supervisors believes that the personnel listed in the list of incentive objects granted for the first time in the company's incentive plan have the qualifications specified in the company law and other laws, regulations, normative documents and the articles of association, and there is no situation that they have been identified as inappropriate candidates by the stock exchange in the last 12 months; There is no situation in which the CSRC and its dispatched offices have identified them as inappropriate candidates in the last 12 months; There are no cases in which the CSRC and its dispatched offices have imposed administrative penalties or taken market entry prohibition measures for major violations of laws and regulations in the last 12 months; There is no circumstance that the company is not allowed to serve as a director or senior manager of the company as stipulated in the company law; There is no case that the company is not allowed to participate in the equity incentive of listed companies according to laws and regulations, which meets the incentive object conditions specified in the administrative measures for equity incentive of listed companies and the Listing Rules of GEM stocks of Shenzhen Stock Exchange, and the scope of incentive objects specified in the company's restricted stock incentive plan (Draft) in 2022 and its summary, Its subject qualification as the incentive object of the company's restricted stock incentive plan in 2022 is legal and effective.
The company will publicize the names and positions of incentive objects within the company through the company's website or other channels before the general meeting of shareholders, and the publicity period shall not be less than 10 days. After fully listening to the publicity opinions, the board of supervisors will disclose the audit opinions on the list of incentive objects and the explanation of publicity five days before the shareholders' meeting deliberates the incentive plan. For details, see the relevant announcement of the company published on cninfo.com, the gem information disclosure website designated by the CSRC on March 25, 2022.
Voting result: Yes: 3 votes; Against: 0 votes; Abstention: 0 votes.
3、 Documents for future reference
1. Resolution of the 4th meeting of Hybio Pharmaceutical Co.Ltd(300199) the 5th board of supervisors;
2. Other documents required by Shenzhen Stock Exchange.
It is hereby announced.
Hybio Pharmaceutical Co.Ltd(300199) board of supervisors March 25, 2022
